Early arrhythmia recurrence after catheter ablation for persistent atrial fibrillation: is it predictive for late recurrence?


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 24 01 2021
accepted: 30 08 2021
pubmed: 15 9 2021
medline: 15 2 2022
entrez: 14 9 2021
Statut: ppublish

Résumé

Early recurrence of atrial tachyarrhythmia (ERAT) is common after radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF), but its clinical significance in patients with persistent AF remains unclear. We sought to determine the predictive value of ERAT for rhythm outcome after RFCA for persistent AF. The study included 207 consecutive patients (mean age 66.4 ± 10.7 years, male 66.2%) with persistent and long-standing persistent AF undergoing de novo pulmonary vein isolation (± atrial substrate ablation). All patients remained off antiarrhythmic drugs. ERAT was defined as any atrial arrhythmia ≥ 30 s occurring within the first 30 days. Late recurrence (LR) was determined during follow-up visits scheduled 1, 3, 6 and 12 months post-ablation using 7-day Holter ECGs. ERAT occurred in 143/207 (69.1%) patients as AF (60%) or atrial tachycardia (40%) and was persistent in 82% of cases. During a median follow-up of 22.2 months, LR occurred significantly more often in patients with ERAT than in patients without ERAT (92.3 vs. 43.8%, P < 0.001). The only independent predictors for LR were ERAT (OR 16.8, 95% CI 6.184-45.797, P < 0.001) and intraprocedural termination to sinus rhythm (OR 0.052, 95% CI 0.003-0.851, P = 0.038). Extending the blanking period from 30 to 90 days did not impact LR rates. ERAT following ablation of persistent AF is strongly associated with late arrhythmia recurrence, which challenges the assumption that ERAT represents merely a transient phenomenon. While limiting the blanking period to 30 days seems justified, the benefit of early re-ablations remains to be addressed in future studies.

Sections du résumé

BACKGROUND BACKGROUND
Early recurrence of atrial tachyarrhythmia (ERAT) is common after radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF), but its clinical significance in patients with persistent AF remains unclear. We sought to determine the predictive value of ERAT for rhythm outcome after RFCA for persistent AF.
METHODS METHODS
The study included 207 consecutive patients (mean age 66.4 ± 10.7 years, male 66.2%) with persistent and long-standing persistent AF undergoing de novo pulmonary vein isolation (± atrial substrate ablation). All patients remained off antiarrhythmic drugs. ERAT was defined as any atrial arrhythmia ≥ 30 s occurring within the first 30 days. Late recurrence (LR) was determined during follow-up visits scheduled 1, 3, 6 and 12 months post-ablation using 7-day Holter ECGs.
RESULTS RESULTS
ERAT occurred in 143/207 (69.1%) patients as AF (60%) or atrial tachycardia (40%) and was persistent in 82% of cases. During a median follow-up of 22.2 months, LR occurred significantly more often in patients with ERAT than in patients without ERAT (92.3 vs. 43.8%, P < 0.001). The only independent predictors for LR were ERAT (OR 16.8, 95% CI 6.184-45.797, P < 0.001) and intraprocedural termination to sinus rhythm (OR 0.052, 95% CI 0.003-0.851, P = 0.038). Extending the blanking period from 30 to 90 days did not impact LR rates.
CONCLUSION CONCLUSIONS
ERAT following ablation of persistent AF is strongly associated with late arrhythmia recurrence, which challenges the assumption that ERAT represents merely a transient phenomenon. While limiting the blanking period to 30 days seems justified, the benefit of early re-ablations remains to be addressed in future studies.

Identifiants

pubmed: 34519875
doi: 10.1007/s00392-021-01934-8
pii: 10.1007/s00392-021-01934-8
pmc: PMC8766394
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

85-95

Informations de copyright

© 2021. The Author(s).

Références

J Cardiovasc Electrophysiol. 2009 Oct;20(10):1089-94
pubmed: 19549038
Eur Heart J. 2014 Dec 14;35(47):3356-64
pubmed: 25182250
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):83-9
pubmed: 24446024
Circ Arrhythm Electrophysiol. 2016 Aug;9(8):
pubmed: 27516462
J Cardiovasc Electrophysiol. 2012 Dec;23(12):1295-301
pubmed: 22897339
Pacing Clin Electrophysiol. 2020 Oct;43(10):1156-1164
pubmed: 32895960
Pacing Clin Electrophysiol. 1996 Apr;19(4 Pt 1):484-9
pubmed: 8848397
JACC Clin Electrophysiol. 2017 Jun;3(6):568-576
pubmed: 29759429
Sci Rep. 2018 Jun 29;8(1):9875
pubmed: 29959347
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):69-75
pubmed: 24446022
Eur Heart J. 2016 Feb 14;37(7):610-8
pubmed: 26417061
J Cardiovasc Electrophysiol. 2013 Apr;24(4):388-95
pubmed: 23252615
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):846-52
pubmed: 26108982
Heart Rhythm. 2021 Mar;18(3):366-373
pubmed: 33242668
Heart Rhythm. 2008 May;5(5):679-85
pubmed: 18325850
J Cardiovasc Electrophysiol. 2009 Dec;20(12):1321-5
pubmed: 19602031
J Cardiovasc Electrophysiol. 2020 Mar;31(3):674-681
pubmed: 31984563
J Cardiovasc Electrophysiol. 1999 Mar;10(3):336-42
pubmed: 10210495
Pacing Clin Electrophysiol. 2012 Jan;35(1):106-16
pubmed: 22054110
Circulation. 1999 Nov 30;100(22):2237-43
pubmed: 10577997
J Cardiovasc Electrophysiol. 2008 Jun;19(6):599-605
pubmed: 18462321
Europace. 2018 Jan 1;20(1):e1-e160
pubmed: 29016840

Auteurs

Miruna A Popa (MA)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany. popa@dhm.mhn.de.

Marc Kottmaier (M)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Elena Risse (E)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Marta Telishevska (M)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Sarah Lengauer (S)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Katharina Wimbauer (K)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Amir Brkic (A)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Verena Kantenwein (V)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Stephanie Ulrich (S)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Marielouise Kornmayer (M)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Hannah Krafft (H)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Monika Hofmann (M)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Susanne Kathan (S)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Tilko Reents (T)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Isabel Deisenhofer (I)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Gabriele Hessling (G)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Felix Bourier (F)

Department of Electrophysiology, German Heart Center Munich, Technical University Munich, Lazarettstr. 36, 80636, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH